Trump's Executive Order on Psychedelic Research
President Trump signed an executive order aimed at accelerating the federal review process for psychedelics. The order seeks to expand access to psychedelic drug treatments for mental health, specifically mentioning substances like ibogaine, LSD, and psilocybin.
Latest Developments
What to Know About Trump’s New Executive Order on Psychedelic Drugs
President Donald Trump signed an executive order on April 18, 2026, aimed at accelerating the development of psychedelic drugs as medical treatments. The order directs the Food and Drug Administration (FDA) to give expedited consideration to psychedelics meeting certain criteria and allocates $50 million from the Department of Health and Human Services to match state research investments. This move signals the administration's unusual openness to considering federally banned substances like LSD, MDMA, and psilocybin as potential treatments for conditions such as treatment-resistant depression and PTSD. While it doesn't change FDA safety and efficacy evidence requirements, it could significantly impact the budding psychedelic industry by offering manufacturers accelerated review timelines of 1-2 months. Harvard Law School's Mason Marks notes this could encourage states to fund research and represents a shift from past federal drug policies.
Trump order could fast-track review of psychedelic ibogaine. What is it?
President Trump signed an executive order Saturday to expedite the review process for psychedelic drugs, specifically mentioning ibogaine. This action aims to accelerate the evaluation of these substances for potential medical applications. The order could significantly shorten the timeline for federal agencies to assess the safety and efficacy of psychedelics. This move indicates a growing interest within the Trump administration in exploring alternative treatments, particularly for conditions like addiction or mental health disorders.
Grassley undergoes procedure to remove gallstones
Sen. Chuck Grassley (R) underwent surgery over the weekend to remove gallstones, as he announced Monday on social platform X. The 92-year-old nine-term incumbent stated he will return to Capitol Hill as soon as possible following the procedure in Iowa. Grassley currently serves as the chair of the Senate Judiciary Committee. His temporary absence could affect legislative proceedings, though he expects a swift return.
Kevin Warsh set to face lawmakers in Fed chair confirmation hearing
Kevin Warsh is scheduled to appear before lawmakers for his confirmation hearing as President Trump's nominee for Fed chair. Warsh is nominated to succeed Jerome Powell in the role, which oversees the nation's central bank. Senators are expected to question Warsh extensively on his perspectives regarding inflation and interest rates during the hearing. His confirmation would place him at the helm of monetary policy decisions for the United States.
Ramaswamy almost tied with Democrat Acton in Ohio governor race: Poll
A new poll conducted by Bowling Green State University (BGSU) shows GOP frontrunner Vivek Ramaswamy and presumptive Democratic nominee Amy Acton are nearly tied in the Ohio gubernatorial race. The survey of 1,000 registered voters in Ohio found 48 percent support for Ramaswamy. This indicates a dead heat between the two candidates for the state's top executive office. The poll highlights a potentially competitive election in the Buckeye State.
Key Facts
President Trump signed an executive order to accelerate the federal review process for psychedelics.
Source: Al Jazeera, CBS News
The order aims to expand access to psychedelic drug treatments for mental health.
Source: The Guardian US News, The Hill
Specific psychedelics mentioned include ibogaine, LSD, and psilocybin.
Source: CBS News, AP News
Joe Rogan joined Trump at the signing event.
Source: Al Jazeera, The Hill
Recent Highlights
The White House issues a statement on accelerating medical treatments for serious mental illness, including psychedelics.
President Trump, joined by Joe Rogan, signs an executive order to speed up psychedelic review.
Full Coverage (24 articles)
Showing 20 of 24 articles
What to Know About Trump’s New Executive Order on Psychedelic Drugs
President Donald Trump signed an executive order on April 18, 2026, aimed at accelerating the development of psychedelic drugs as medical treatments. The order directs the Food and Drug Administration (FDA) to give expedited consideration to psychedelics meeting certain criteria and allocates $50 million from the Department of Health and Human Services to match state research investments. This move signals the administration's unusual openness to considering federally banned substances like LSD, MDMA, and psilocybin as potential treatments for conditions such as treatment-resistant depression and PTSD. While it doesn't change FDA safety and efficacy evidence requirements, it could significantly impact the budding psychedelic industry by offering manufacturers accelerated review timelines of 1-2 months. Harvard Law School's Mason Marks notes this could encourage states to fund research and represents a shift from past federal drug policies.
Trump order could fast-track review of psychedelic ibogaine. What is it?
President Trump signed an executive order Saturday to expedite the review process for psychedelic drugs, specifically mentioning ibogaine. This action aims to accelerate the evaluation of these substances for potential medical applications. The order could significantly shorten the timeline for federal agencies to assess the safety and efficacy of psychedelics. This move indicates a growing interest within the Trump administration in exploring alternative treatments, particularly for conditions like addiction or mental health disorders.
Grassley undergoes procedure to remove gallstones
Sen. Chuck Grassley (R) underwent surgery over the weekend to remove gallstones, as he announced Monday on social platform X. The 92-year-old nine-term incumbent stated he will return to Capitol Hill as soon as possible following the procedure in Iowa. Grassley currently serves as the chair of the Senate Judiciary Committee. His temporary absence could affect legislative proceedings, though he expects a swift return.
Kevin Warsh set to face lawmakers in Fed chair confirmation hearing
Kevin Warsh is scheduled to appear before lawmakers for his confirmation hearing as President Trump's nominee for Fed chair. Warsh is nominated to succeed Jerome Powell in the role, which oversees the nation's central bank. Senators are expected to question Warsh extensively on his perspectives regarding inflation and interest rates during the hearing. His confirmation would place him at the helm of monetary policy decisions for the United States.
Ramaswamy almost tied with Democrat Acton in Ohio governor race: Poll
A new poll conducted by Bowling Green State University (BGSU) shows GOP frontrunner Vivek Ramaswamy and presumptive Democratic nominee Amy Acton are nearly tied in the Ohio gubernatorial race. The survey of 1,000 registered voters in Ohio found 48 percent support for Ramaswamy. This indicates a dead heat between the two candidates for the state's top executive office. The poll highlights a potentially competitive election in the Buckeye State.
Trump sees approval dip the most among young voters in poll
President Trump's approval rating has declined most significantly among young adults, according to a new NBC News poll. The NBC News Decision Desk Poll, powered by Survey Monkey and released Sunday, indicates that 76 percent of Americans under 30 disapprove of the president’s job performance. This demographic shift suggests a potential challenge for the Trump administration in securing support from younger voters. The poll also noted that 24 percent of voters in this age group approve of the president's performance.
President Trump’s Landmark Order Advances Breakthrough Mental Health Treatments — Delivering New Hope to Veterans - The White House (.gov)
President Trump signed a landmark order to advance breakthrough mental health treatments, specifically aimed at delivering new hope to veterans. This initiative focuses on accelerating access to innovative therapies for those suffering from mental health challenges. The order signifies a White House commitment to improving mental healthcare for service members and veterans, addressing a critical need within this population. It aims to streamline processes for developing and deploying cutting-edge treatments.
The Federal Move That Sent Psychedelics Stocks Flying - Investor's Business Daily
A federal move caused a significant surge in the stock prices of companies in the psychedelics sector. This action by the U.S. government directly impacted investor confidence and market valuation for businesses focused on psychedelic compounds. The immediate consequence was a notable increase in the value of psychedelics stocks, as reported by Investor's Business Daily. This suggests a perceived shift in regulatory or policy outlook that investors believe will benefit the industry.
Psychedelic drug makers rally as Trump orders FDA to expedite reviews - Yahoo Finance
President Trump has ordered the Food and Drug Administration (FDA) to expedite reviews of psychedelic drugs, leading to a rally among psychedelic drug makers. This directive signals a significant shift in federal policy regarding these substances, potentially accelerating their path to market for therapeutic uses. The move could open new avenues for mental health treatments, as companies developing psychedelics for conditions like PTSD and depression stand to benefit from faster regulatory approval. This action by the Trump administration reflects a growing interest in the potential medical applications of psychedelics.
Trump-branded AI data center megaproject stalls, CEO departs
CEO Toby Neugebarger abruptly departed Fermi America, a Trump-branded AI data center project, on Friday amidst delays and logistical hurdles. The company's shares, which had already shed 75% in the last six months, plummeted further in aftermarket trading following the announcement. This departure comes as the project, known as Project Matador, faces challenges including the lack of a publicly confirmed anchor tenant and difficulties with cooling systems. An independent report by Cleanview estimates the first buildings wouldn't come online until May 2027, about a year later than initially projected. Fermi America, co-founded by President Trump's former Energy Secretary Rick Perry, is a high-profile test for ambitious AI infrastructure projects.
Trump signs executive order accelerating research into psychedelic drug therapies
President Donald Trump signed an executive order Saturday to accelerate research and approval of psychedelic-based therapies. This order specifically targets conditions like PTSD, aiming to streamline the development of these treatments. The move signals the Trump administration's intent to explore alternative medical approaches for mental health and trauma. This initiative could potentially broaden access to novel treatments for veterans and others suffering from these conditions.
Trump signs order fast tracking review of psychedelics for mental health disorders
President Donald Trump signed an order to fast-track the review of psychedelics for mental health disorders. The President endorsed psilocybin and ibogaine as part of this initiative. This action aims to accelerate the evaluation process for these substances. The order reflects a White House focus on potential alternative treatments for mental health.
Trump signs order fast tracking review of psychedelics for mental health disorders - NPR
President Donald Trump signed an order to fast-track the review of psychedelics for mental health disorders, as reported by NPR. This executive action aims to accelerate the process by which certain psychedelic substances, like psilocybin or MDMA, could be approved for therapeutic use. The move reflects a growing interest in exploring alternative treatments for conditions such as PTSD, depression, and anxiety, which have shown promising results in preliminary studies. By expediting the review, the Trump administration is signaling a shift in federal policy regarding these previously restricted substances. This could potentially lead to quicker access to new treatment options for millions of Americans suffering from mental health challenges.
Trump joined by Joe Rogan as he signs order to speed up psychedelic review
President Trump, joined by Joe Rogan, signed an order aimed at accelerating the federal review process for psychedelics. The executive order specifically directs the federal government to relax restrictions on psychedelics, including ibogaine, for their potential use as treatments. This action signals a significant shift in federal policy regarding these substances, potentially easing their path toward medical applications. The move could facilitate research and development into psychedelic-assisted therapies for various conditions.
Watch: Trump signs executive order easing U.S. restrictions on psychedelic research
President Trump signed an executive order on Saturday to ease restrictions on research into psychedelics. This order specifically mentions the drug ibogaine, which is used in some countries to treat post-traumatic stress disorder. The move signals a potential shift in the federal government's approach to studying these substances for therapeutic applications. This action could facilitate new scientific investigations into psychedelics as treatments for various conditions.
Trump signs order to hasten review of psychedelics
President Trump signed an order to expedite the review process for psychedelics, aiming to accelerate research into their potential medical applications. This action comes despite psychedelics like Ibogaine remaining in the federal government's most restrictive category for illegal, high-risk drugs. The Trump administration is seeking to ease current restrictions to spur studies on using these substances for conditions such as severe depression. This initiative could lead to significant changes in how psychedelics are researched and potentially utilized for therapeutic purposes in the United States.
Trump announces reforms to accelerate access to psychedelic drug treatments
President Donald Trump signed an executive order on Saturday to accelerate access to psychedelic drug treatments. The order specifically directs the federal Food and Drug Administration (FDA) to expedite its review process for psychedelic drugs, including ibogaine. This action aims to speed up medical research and treatment options for conditions like post-traumatic stress disorder (PTSD). US military veteran groups have advocated for ibogaine, citing its potential to treat PTSD. The Trump administration's move could significantly alter the regulatory landscape for these substances.
Trump orders more access to psychedelics like LSD, psilocybin, ibogaine - The Washington Post
President Donald Trump has ordered increased access to psychedelics such as LSD, psilocybin, and ibogaine. This directive aims to expand the availability of these substances, which are currently largely illegal, for therapeutic or research purposes. The move signals a significant shift in federal policy regarding controlled substances, potentially facilitating new treatments for mental health conditions. This decision could accelerate research into the medical benefits of psychedelics and influence future regulatory frameworks. The order from the White House reflects a growing interest in the potential of these compounds beyond their recreational use.
Trump signs order to accelerate access to psychedelic drug treatments - Reuters
President Donald Trump signed an order to accelerate access to psychedelic drug treatments. This action aims to expand the availability of these substances for therapeutic use, particularly in mental health care. The order signals a significant push from the Trump administration to explore and utilize psychedelics for medical purposes. This move could impact research, regulatory pathways, and patient access to treatments for conditions like PTSD or depression.
Joe Rogan joins Trump to sign order allowing psychedelic drug research
President Trump signed an executive order in the Oval Office on Saturday to accelerate research into certain psychedelic drugs for mental health treatment, with podcaster Joe Rogan present. The order aims to help individuals suffering from debilitating mental health symptoms. This action signifies a federal push to explore alternative treatments for mental health disorders, potentially expanding therapeutic options. The presence of Joe Rogan, a prominent advocate for psychedelic research, highlights the growing public interest and support for these substances. The Trump administration's initiative could lead to new avenues for mental health care.